Latest Conference Articles

Pharmacists can also play a role in SDOH by replacing drug delivery with something else, such as food or transportation delivery, according to speakers at the ATOPP conference.

The European Union (EU) has successfully created a competitive market for biosimilars, while the US faces challenging market dynamics and tactics by pharmacy benefit managers that hinder the adoption of lower-cost therapies.

Collaboration between community centers and academic medical centers can improve patient access to these complex therapies.

Approximately 81% of individual said Tandem Mobi reduced the burden of managing diabetes and 87% said it helped manage diabetes effectively.

Laura Bray, founder of Angels for Change, explains that addressing the 4 key economic causes to drug shortages can also help lead to effective solutions long-term.

American Diabetes Association Scientific Sessions speaker Ivan de Araujo discusses how regulation of blood glucose levels and the influence of food preferences can be significant for diabetes care.

Site-of-care considerations can pose challenges with these therapies.

Heath Mart, part of McKesson, offers an online resource to locate resources near independent pharmacies.

Heidi Finnes, PharmD, BCOP, FHOPA, discusses the evolving landscape of treatment for patients with cutaneous malignancies and melanoma.

These findings build off research from March 2023 that demonstrated efficacy and safety of renizgamglogene autogedtemcel in patients with sickle cell disease.

Pharmacies can position themselves as leaders in immunization services.

McKesson is helping to address financial challenges facing independent pharmacies.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, discusses the impact of CAR T cell and bispecific therapies in treatment of patients with hematological malignancies.

Rose DiMarco, PharmD, BCPS, BCOP, shares insights into the evolving treatment landscape for patients with breast cancer with specific mutations.

Shahida Choudhry, PharmD, shares her journey in pharmacy ownership.

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discusses the crucial role pharmacists play in providing supportive care for patients with cancer.

Benefits of semaglutide on cardiovascular outcomes, such as death, non-fatal myocardial infarction, and non-fatal stoke, were also presented at the session at American Diabetes Association 84th Scientific Sessions.

Jordyn P. Higgins, PharmD, BCOP, discusses the evolving treatment landscape for small cell lung cancer (SCLC).

Teplizumab (Tzield; Sanofi) has the potential to delay type 1 diabetes and the onset of stage 3 diabetes, but must be started in stage 1 of the disease.

Questions arise around equity and revenue challenges.

Food is medicine is a framework of policy and behavioral interventions, improving population health through access to healthy foods to increase food and nutrition security.

Niki Shah Vice President of Impact Innovation and Activation at McKesson, discusses efforts to advance health equity and access through community pharmacy initiatives.

W. Timothy Garvey expressed concern over limited access to effective obesity medications like Ozempic due to shortages and high costs, urging stakeholders to work together on developing solutions.

Semaglutide significantly improved heart failure symptoms and quality of life through weight loss and direct effects on heart tissue.

Adding a community health worker can improve the overall health equity for your patients.

Potential concerns surrounding GLP-include pancreatitis, pancreatic cancer, colorectal cancer, suicide and other phycological effects, and thyroid cancer.

Jennifer Goldman discusses the importance of collaborative care between providers like endocrinologists, cardiologists, primary care physicians, and pharmacists to manage diabetes and prevent cardiovascular events.

There are approximately 98 million individuals have prediabetes, but approximately only 15 million actually know they have prediabetes.

Semaglutide was found to have effects on glycemia, inflammation, and heart failure outcomes in sub analyses.

Based on these results, tirzepatide could be first medication approved for treatment of obstructive sleep apnea in patients with obesity.